CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Analysts

CVRx, Inc. (NASDAQ:CVRXGet Free Report) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $17.00.

A number of brokerages recently issued reports on CVRX. Lake Street Capital increased their target price on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 price objective on shares of CVRx in a report on Wednesday, October 23rd. William Blair raised shares of CVRx from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 14th. Canaccord Genuity Group lifted their price target on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th.

Get Our Latest Report on CVRX

Hedge Funds Weigh In On CVRx

Several institutional investors have recently bought and sold shares of CVRX. SG Americas Securities LLC bought a new stake in shares of CVRx in the third quarter valued at $108,000. Calamos Advisors LLC bought a new stake in CVRx in the 4th quarter valued at about $134,000. XTX Topco Ltd purchased a new stake in CVRx during the third quarter valued at about $150,000. Jane Street Group LLC boosted its position in CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after purchasing an additional 5,053 shares during the period. Finally, Barclays PLC increased its stake in shares of CVRx by 312.5% in the third quarter. Barclays PLC now owns 19,067 shares of the company’s stock worth $169,000 after purchasing an additional 14,445 shares in the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Stock Down 0.2 %

Shares of NASDAQ:CVRX opened at $16.81 on Friday. CVRx has a 1 year low of $6.40 and a 1 year high of $26.55. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. The business’s 50-day moving average is $14.67 and its 200-day moving average is $11.55. The company has a market capitalization of $407.81 million, a price-to-earnings ratio of -6.23 and a beta of 1.26.

CVRx (NASDAQ:CVRXGet Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period last year, the firm posted ($0.43) earnings per share. Equities research analysts predict that CVRx will post -2.61 earnings per share for the current year.

CVRx Company Profile

(Get Free Report

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

Further Reading

Analyst Recommendations for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.